Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis
NCT ID: NCT02026401
Last Updated: 2017-03-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
45 participants
INTERVENTIONAL
2014-02-28
2014-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis
NCT02135536
Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)
NCT02443116
Obeticholic Acid Versus Placebo, in Combination with Ursodeoxycholic Acid in Patients with Primary Biliary Cirrhosis
NCT06715319
Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC)
NCT02955602
Use of Bezafibrate in Patients With Primary Biliary Cirrhosis to Archive Complete Biochemical Response in Non-responders
NCT02937012
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NGM282 Dose 1
NGM282 Dose 1
NGM282
NGM282 Dose 2
NGM282 Dose 2
NGM282
Placebo
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NGM282
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* PBC diagnosis consistent with AASLD and EASL guidelines
* Stable dose of UDCA
Exclusion Criteria
* Evidence of clinically significant hepatic decompensation
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
NGM Biopharmaceuticals Australia Pty Ltd
INDUSTRY
NGM Biopharmaceuticals, Inc
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stephen J Rossi, PharmD
Role: STUDY_DIRECTOR
NGM Biopharmaceuticals, Inc
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
NGM Clinical Study Site 103
Phoenix, Arizona, United States
NGM Clinical Study Site 108
Coronado, California, United States
NGM Clinical Study Site 101
Detroit, Michigan, United States
NGM Clinical Study Site 105
Durham, North Carolina, United States
NGM Clinical Study Site 102
Dallas, Texas, United States
NGM Clinical Study Site 113
San Antonio, Texas, United States
NGM Clinical Study Site 104
Richmond, Virginia, United States
NGM Clinical Study Site 602
Sydney, New South Wales, Australia
NGM Clinical Study Site 606
Sydney, New South Wales, Australia
NGM Clinical Study Site 609
Sydney, New South Wales, Australia
NGM Clinical Study Site 611
Sydney, New South Wales, Australia
NGM Clinical Study Site 614
Brisbane, Queensland, Australia
NGM Clinical Study Site 607
Adelaide, South Australia, Australia
NGM Clinical Study Site 608
Adelaide, South Australia, Australia
NGM Clinical Study Site 601
Melbourne, Victoria, Australia
NGM Clinical Study Site 604
Melbourne, Victoria, Australia
NGM Clinical Study Site 613
Melbourne, Victoria, Australia
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
13-0103
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.